Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

AJMC
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021

July 31st 2025

Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.

PFAS | Image credit: Vodkaz - stock.adobe.com
PFAS Exposure Linked to Increased Risk of Type 2 Diabetes, Study Finds

July 29th 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com
SGLT2i-Induced Erythrocytosis Not Linked to Clots in Type 2 Diabetes

July 21st 2025

MRI head brain scan - DedMityay - stock.adobe.com
Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

July 18th 2025

Doctor examines eye anatomy model using magnifying glass | Image credit: Viktor - stock.adobe.com
Clinical Data Predicts Risk of Progression to Proliferative Diabetic Retinopathy

July 15th 2025

Advancing Care in Type 2 Diabetes and Obesity: A Coordinated, Guideline-Driven Approach

Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.

AJMC Peer Exchange geometric background
Continuing Medical Education
View All
July 31st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 31st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Ozempic | Image credit: mbruxelle – stock.adobe.com
June 20th 2024

WHO Issues Warning for Fake Semaglutide

Hayden E. Klein
Taking falsified semaglutide (Ozempic; Novo Nordisk) can lead to ineffective treatment due to incorrect dosing, contamination, and the use of unknown ingredients, the World Health Organization (WHO) is warning.
Age, Insurance Play Major Roles in CGM Use, Says Dr Chase Hendrickson
June 18th 2024

Age, Insurance Play Major Roles in CGM Use, Says Dr Chase Hendrickson

Hayden E. Klein
Patients with diabetes who have private insurance are more likely to be prescribed a continuous glucose monitor (CGM) compared with those with government insurance, says Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center.
FDA | Image credit: Araki Illustrations – stock.adobe.com
June 13th 2024

FDA Approves Dapagliflozin for Children With Type 2 Diabetes

Hayden E. Klein
Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults.
Semaglutide injections | Image credit: Patrick Bay Damsted – stock.adobe.com
May 24th 2024

Semaglutide Lowers Risk of Major Kidney Outcomes, Cardiovascular Events, Death in Patients With Diabetes and CKD

Hayden E. Klein
Patients who took the weekly glucagon-like peptide 1 (GLP-1) receptor agonist were 21% less likely to experience major kidney disease events and 29% less likely to die due to cardiovascular causes.
Supply of tirzepatide | Image credit: MKPhoto – stock.adobe.com
May 16th 2024

Most Insured Adults Still Have to Pay at Least Part of the Cost of GLP-1 Drugs

Hayden E. Klein
Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.
Art Masturzo, MD, MBA
May 6th 2024

Dr Arti Masturzo Gives an In-Depth Look at CCS Survey Results Showing Misconceptions Around Diabetes Management

Hayden E. Klein
Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.
Joanne Mizell
May 1st 2024

Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease

Giuliana Grossi
Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Beau Raymond, MD
April 18th 2024

Dr Beau Raymond on Value-Based Diabetes Care: How Healthy State Initiatives Prevent Downstream Effects

Hayden E. Klein Maggie L. Shaw
Beau Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, explains the importance of diabetes and hypertension control to prevent downstream events such as heart attacks and strokes.
Continuous glucose monitor | Image credit: habrovich – stock.adobe.com
April 17th 2024

Beyond Insulin: The Impact of Next-Generation Diabetes Technology

Hayden E. Klein Laura Joszt, MA
Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
April 15th 2024

Dr Kevin Malloy Discusses the Evolution of GLP-1 Receptor Agonists

Kyle Munz
Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES, Cleveland Clinic, discusses how GLP-1 receptor agonists have evolved in the treatment landscape of diabetes and obesity at an Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic.
AJMC
April 1st 2024

Medication Persistence and Its Impact on Type 2 Diabetes

Jee H. Choe, MS Si Xuan, PhD Antony Goldenberg, PharmD Jacqueline Matian, PharmD Jeff McCombs, PhD Rory E. Kim, PharmD, MACM, BCACP
Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs.
Woman having eye exam by optometrist | Image Credit: © Nicholas Felix/peopleimages.com - stock.adobe.com
March 19th 2024

Breaking Barriers: Partnerships to Improve Diabetic Eye Health in Alabama

Bryan A. Wilson, PhD, MBA Danielle Haney, PhD Risa Reuscher, PharmD David Tabano, PhD Kimberly Jinnett, PhD Ayesha Ahmed, PharmD Andrew Gordon, MD, PhD Anthony Coleman, BS Raelle Wilson, MA Rachel Israel, BS Jenee Williams, MBA Marina Pevzner Hennessy, MS Terri Wiggins, MS Elizabeth J. Pekas, PhD Raveendhara R. Bannuru, MD, PhD
This article reviews barriers to diabetic eye health across Alabama and highlights a partnership with Genentech and the American Diabetes Association to address this issue.
Survey questionnaire | Image credit: Kay Abrahams peopleimages.com – stock.adobe.com
March 8th 2024

CCS Report Reveals Misconceptions Among People Living With Diabetes; Calls for Enhanced Engagement, Education

Hayden E. Klein
A survey of more than 1500 people revealed misconceptions about living with diabetes, particularly regarding the efficacy of GLP-1 weight loss drugs as a standalone solution for managing their health goals.
AJMC
March 8th 2024

Improving Glycemic Control in Diabetes Through Virtual Interdisciplinary Rounds

Abby F. Hoffman, PhD Cindy Leslie Roberson, PharmD Pamela Cohen, BA Victoria Lee Jackson, PharmD John Yeatts, MD Patrick Gregory, PharmD Samantha Wong, MD Susan E. Spratt, MD
Patients with diabetes whose providers received advice from remote, virtual interdisciplinary rounds had a greater 1-year reduction in hemoglobin A1c than comparable patients.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
March 6th 2024

FDA Approves First Over-the-Counter Continuous Glucose Monitor

Hayden E. Klein
Starting summer 2024, individuals across the US will be able to purchase a continuous glucose monitor (CGM) without needing a prescription.
AJMC
March 5th 2024

Out-of-Pocket Costs for Diabetes Medications in Employer-Sponsored Health Insurance Plans

Jennie Quach, MBA Cody Midlam, PharmD Chantell Sell, PharmD Jeff Levin-Scherz, MD, MBA
Out-of-pocket costs of diabetes medications other than insulin can be quite high for individuals with employer-sponsored health insurance.
what we're reading logo
February 22nd 2024

What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout

AJMC Staff
More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Diabetes medicine graphic | Image credit: vectorfusionart stock.adobe.com
February 15th 2024

Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations

Hayden E. Klein
Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Diabetes management may reduce dementia risk | Image credit: Dragana Gordic – stock.adobe.com
February 12th 2024

Primary Care Diabetes Management May Also Reduce Risk of Dementia

Hayden E. Klein
Participants in the Risk Assessment and Management Program-Diabetes Mellitus had reduced risks of developing all-cause dementia by 28%, Alzheimer disease by 15%, vascular dementia by 39%, and other or unspecified dementia by 29%.
Pill bottle with dollars in it | Image credit: Cagkan – stock.adobe.com
February 9th 2024

Lowering Cardiometabolic Drug Costs May Improve Diabetes Health Outcomes

Hayden E. Klein
Patients enrolled in a preventive drug list (PDL) benefit saw an 8.4% reduction in acute, preventable diabetes complication days, and PDL members residing in lower-income areas saw a 10.2% decrease compared with control members.
pregnant woman using insulin pump | Image credit: lukszczepanski – stock.adobe.com
February 8th 2024

Diabetes Management During Pregnancy: Insights From 3 Specialists

Hayden E. Klein Laura Joszt, MA
Experts explain how diabetes is diagnosed during pregnancy, how treatment differs from that of nonpregnant individuals, the importance of diabetes technology education, and how things change postpartum.
COVID-19 | Image Credit: Production Perig - stock.adobe.com
February 1st 2024

Review: COVID-19 Pandemic Impact on Clinical Outcomes in Patients With Diabetes

Brooke McCormick
This systematic review found COVID-19 disruptions on clinical outcomes in those with diabetes to be more pronounced for females, younger people, and those a part of racial and ethnic minority groups.
Pharmacists conversing | Image credit: Gorodenkoff – stock.adobe.com
January 27th 2024

Impact of a Pharmacist-Managed TOC Clinic on Diabetes Outcomes Following Hospitalization

Hayden E. Klein
While the clinic did not significantly reduce hospital readmission rates for patients with diabetes, it was able to decrease the time to follow-up and improve long-term diabetes outcomes following hospitalization.
The Americas | Image credit: Віталій Баріда – stock.adobe.com
January 25th 2024

Diabetes Mortality Trends Were Stable in the Americas Over 20-Year Period

Hayden E. Klein
An analysis covered trends in mortality caused by diabetes and diabetic kidney disease across North, South, and Central America from 2000 to 2019.
HbA1c test | Image credit: jarun011 – stock.adobe.com
January 23rd 2024

HbA1c Above 6% Linked to Much Greater Diabetes Risk in Adolescents

Hayden E. Klein
Compared with a hemoglobin A1c (HbA1c) level of 5.5%, adolescents with overweight or obesity were 72 times more likely to have diabetes if their HbA1c was 6.3% to 6.4%.
Ian Neeland, MD
January 11th 2024

What Happens to Patients With Diabetes When Semaglutide Dosing Is Disrupted? Dr Ian Neeland Explains

Hayden E. Klein
Possible long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events.
the top 5 videos of 2023
December 28th 2023

Top 5 Most-Viewed Videos of 2023

Hayden E. Klein
Our most-viewed videos include interviews about a type 2 diabetes reversal program with impressive 6-month results, concerns over service denials in certain health plans, the Enhancing Oncology Model, and more.
the top 5 diabetes articles of 2023
December 19th 2023

Top 5 Diabetes Articles of 2023

Hayden E. Klein
Our most-read articles on diabetes covered racial biases in type 2 diabetes risk prediction models, cardiovascular disease as a leading cause of hospital admissions in patients with diabetes, and much more.
highlights from kidney week 2023
December 13th 2023

ICYMI: Highlights From Kidney Week 2023

Hayden E. Klein
Our most-read coverage of American Society of Nephrology Kidney Week 2023 highlighted discussions on the challenges of medication dose adjustments in chronic kidney disease, the impact of LGBTQ+ health care disparities on kidney outcomes, and much more.
Metformin | Image credit: Sherry Young – stock.adobe.com
December 12th 2023

Metformin Does Not Improve Neonatal Outcomes for Pregnant Patients With Diabetes

Hayden E. Klein
Adding metformin to the insulin regimen for pregnant patients with preexisting type 2 diabetes (T2D) or gestational diabetes diagnosed early in pregnancy did not reduce the risk of neonatal adverse outcomes.
<12345678
...
98>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo